Anbio Biotechnology (NASDAQ:NNNN) Stock Price Down 5.5% – Here’s Why

Anbio Biotechnology (NASDAQ:NNNN)’s stock price dropped 5.5% on Wednesday . The company traded as low as $27.00 and last traded at $27.25. Approximately 18,667 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 52,552 shares. The stock had previously closed at $28.84.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 1st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Anbio Biotechnology presently has a consensus rating of “Sell”.

Anbio Biotechnology Stock Performance

The stock’s 50-day simple moving average is $24.55.

Anbio Biotechnology (NASDAQ:NNNN) last posted its quarterly earnings data on Tuesday, April 7th. The company reported $0.03 earnings per share for the quarter.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.